Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference
Retrieved on:
Tuesday, September 27, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Risk, Fanconi anemia, Investor, Safety, COVID-19, FA, AAV, Pyruvate kinase deficiency, Danon disease, PKD, Lists of diseases, Private Securities Litigation Reform Act, Westin Hotels & Resorts, Heart failure, Patient, Westin Hotel Cleveland, Bone marrow failure, LVV, Genetic disorder, Medication, NASDAQ, Conference, Marketing, SEC, Pharmaceutical industry
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on Tuesday, Oct. 4, at 2:00 p.m.
Key Points:
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on Tuesday, Oct. 4, at 2:00 p.m.
- A live audio webcast of the presentation will be available under Events in the Investors section of the Companys website at https://ir.rocketpharma.com .
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders.
- Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes.